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h-Caldesmon in vascular smooth muscle is phosphorylated in response to pharmacologic stimulation. Although many kinases phosphorylate 
h-caldesmon, in vitro, the responsible kinase in intact tissue is unknown. The sites of phosphorylation in caldesmon from intact canine aortas have 
recently been identified and are consensus equences for a proline-directed protein kinase. In this study, we investigated the phosphorylation of 
h-caldesmon by mitogen-activated protein kinase (MAPK). Purified, recombinant MAPK phosphorylated porcine stomach h-caldesmon to a 
stoichiometry approaching 2 mol phosphate/m01 protein. Phosphorylated h-caldesmon was subjected to proteolysis and the phosphopeptides were 
purified by high performance liquid chromatography. Two major phosphopeptides were identified and sequenced. These two peptides, VTS * PTKV 
and S * PAPK, were identical to the sequences of the sites phosphorylated in intact tissue. Antibodies to several enzymes implicated in the cascade 
of activation of MAPK were used to evaluate vascular smooth muscle by Western blotting. All components were found to be present. These data 
suggest hat MAPK can function as a ‘caldesmon kinase’ in vascular smooth muscle. 
Caldesmon; Mitogen-activated protein kinase; Vascular smooth muscle 
1. INTRODUCTION 
Mammalian h-caldesmon is a 93 kDa actin-binding 
protein present in both vascular and non-vascular 
smooth muscles [1,2]. h-Caldesmon can cross-link actin 
to myosin via binding of the N-terminus of caldesmon 
to the S2 region of myosin heavy chain, and binding of 
the C-terminus to the amino-terminal domain of actin 
[3]. In arterial smooth muscle h-caldesmon can be 
phosphorylated in response to pharmacologic stimula- 
tion [4,5]. In particular, agonists which stimulate sus- 
tained or tonic contraction of the muscle also increased 
the level of phosphate incorporated into h-caldesmon. 
Several kinases have been reported to phosphorylate 
h-caldesmon in vitro, including protein kinase C [6-81 
and Ca*‘/calmodulin-dependent protein kinase II [9]. 
However, the kinase responsible for h-caldesmon phos- 
phorylation in the intact smooth muscle, has not been 
identified with certainty. Recently, the sequences of the 
sites phosphorylated in intact canine aortas were deter- 
mined and found to be: VTS * PTKV and S * PAPK 
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[8]. These sequences implicated a proline-directed pro- 
tein kinase as the endogenous caldesmon kinase. 
Two main families of proline-directed protein kinases 
have been described: ~34”~“~ and mitogen-activated pro- 
tein kinase (MAPK). ~34~~“~ is the protein kinase com- 
ponent of maturation promoting factor (MPF) which is 
involved in cell cycle regulation in proliferating cells 
[lo]. MPF has not been identified in the contractile 
phenotype of vascular smooth muscle. MAPK, also 
known as extracellular signal-regulated kinase (or 
ERK) is present in some muscles and can phosphorylate 
gizzard caldesmon, in vitro [l 11. There are at least three 
isoenzymes of MAPK [12] and, as the name would 
imply, these enzymes have been implicated in growth 
factor-mediated events such as proliferation and hy- 
pertrophy. In other tissues, MAPK is believed to acti- 
vate ribosomal S6 kinase via a cascade that can be 
initiated as a result of protein kinase C stimulation by 
phorbol esters [13,14]. 
In this paper, we present evidence that h-caldesmon 
is phosphorylated by MAPK on two sites that are iden- 
tical to the sites phosphorylated in intact tissue. These 
data suggest hat MAPK is a caldesmon kinase and that 
caldesmon phosphorylation in intact vascular smooth 
muscle can be modulated through a cascade of enzymes 
that lead to activation of MAPK. 
2. EXPERIMENTAL 
2.1. Materials 
Most chemicals and reagents were purchased from Sigma. [“P]ATP 
and [3’P]orthophosphate were obtained from New England Nuclear. 
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Antibodies specific for MAPK and ~32”“~ were purchased from Bi- 
odesign; antibodies pecific for ras were from Oncogene Science; and 
antibodies specific for raf and MAPK-kinase (anti-STE7-VIII) were 
from Upstate Biotechnology Inc. 
2.2. Proteins 
h-Caldesmon was purified from porcine stomachs as previously 
described [15]. ~34~~“~ was purified from colcemid-treated HeLa cells 
using pl3-Sepharose chromatography [16]. Purified, recombinant, rat 
skeletal muscle MAPK was a gift from Dr. Tim Haystead (University 
of Virginia). 
2.3. Phosphorylation reactions 
For sequencing analysis, h-caldesmon (1 mg) was phosphorylated 
by MAPK in 1 ml of a buffer consisting of 12.5 mM MOPS, pH 7.2, 
0.25 mM [32P]ATP, 12.5 mM&glycerophosphate, 7.5 mM MgQ. 0.5 
mM EGTA, 50 PM sodium fluoride, 0.5 mM sodium orthovanadate 
and 2 mM dithiothreitol. After termination of the reaction by boiling, 
phosphorylated h-caldesmon was separated from [‘*P]ATP on a col- 
umn of Sephacryl S-200 developed with 50 mM NH4HC0, and di- 
gested with S. aureus protease. For time-course experiments, h-cal- 
desmon (0.125 mglml) was phosphorylated in the same buffer for 
varying lengths of time. The reactions were initiated by the addition 
of ATP, terminated by the addition of SDS-sample buffer, and h- 
caldesmon was separated from ATP by polyacrylamide gel electro- 
phoresis. 
2.4. High performance liquid chromatography and peptide sequencing 
Phosphopeptides were purified by HPLC using a combination of 
Cl 8 reverse-phase chromatography and anion-exchange chromatog- 
raphy utilizing an MA7P column from Bio-Rad. Phosphopeptides 
were loaded on the Cl8 column in H,O/O.l% TFA and eluted by 
increasing concentrations of CH,CN/O. 1% TFA. Phosphopeptides 
were eluted from the MA7P column with a gradient of NaCl from 0 
to 500 mM in 10 mM Tris, pH 8.5. Purified phosphopeptides were 
sequenced using an Applied Biosystems model 477 sequencer [8]. 
Phosphoamino acids were prepared from purified phosphopeptides by 
acid hydrolysis at 110°C for 3 h, in vaccuo. Phosphoamino acids were 
separated on cellulose thin layer plates (Kodak) in a buffer consisting 
of acetic acid/formic acid/water (15:5:80) at 10°C. 
“1 
TIME (minutes) 
Fig. 1. Time-course of porcine stomach h-caldesmon phosphorylation 
by ~34~’ and MAPK. h-Caldesmon was phosphorylated as described 
in section 2. Reactions were initiated by the addition of ATP and 
terminated by the addition of SDS. The stoichiometry of phosphoryl- 
ation was determined by gel assay after accurate determination of 
ATP specific activity. Open and filled circles show phosphorylation by 
p34*cz and MAPK, respectively. 
MAPK Intact 
I 
Origin - J 
Fig. 2. Phosphopeptide maps of h-caldesmon phosphorylated in intact 
tissue and by MAPK in vitro. Reactions were performed as described 
in section 2. Thin layer electrophoresis ofboth samples was performed 
concurrently to minimize experimental variability. The mobility of the 
major spots in the intact tissue phosphopeptide map (Intact) corre- 
sponded to the mobility of the sites in the map of h-caldesmon 
phosphorylated by MAPK (MAPK). 
2.5. Phosphopeptide mapping 
Porcine carotid arteries were loaded for 90 min with 32P as previ- 
ously described [4], and then stimulated with 1 PM phorbol-12,13- 
dibutyrate (PDBu) for 60 min. The muscles were then freeze-clamped 
and ground to a fine powder under liquid Nz. h-Caldesmon was puri- 
fied by immunoprecipitation according to procedures we have previ- 
ously described [4]. Phosphorylated h-caldesmon was electrophoreti- 
tally transferred to nitrocellulose and digested with a combination of 
a-chymotrypsin and then TPCK-treated trypsin in a buffer of 50 mM 
NHIHCO,. The phosphopeptides were separated on silica gel-60 thin 
layer plates (EM Science) in a buffer consisting of acetic acid/formic 
acid/water (15:5:80) and subjected to autoradiography. Phosphate 
content in the various caldesmon preparations was determined by the 
method of Buss and Stull [17]. 
2.6. Immune-blotting techniques 
Proteins were extracted from cultured cells by scraping the cells in 
the presence of SDS-sample buffer containing 1 mg/ml each of TPCK 
and TLCK. Proteins were extracted from tissues that were ground to 
a fine powder under liquid N, using the same buffer. Extracted pro- 
teins were separated by SDS-PAGE, transferred to nitrocellulose and 
then probed with the various protein-specific antibodies. SDS-PAGE 
was performed using the buffer system of Porzio and Pearson [18]. 
3. RESULTS 
3.1. Phosphorylation of caldesmon by MAPK and 
p34’dC2 
When porcine stomach h-caldesmon was incubated 
with purified ~34~~, phosphate was incorporated to 
levels greater than 4 mol phosphate/m01 protein (4.4 
mol/mol maximal, Fig. 1). On the other hand, purified 
MAPK incorporated less than 2 mol phosphate/m01 
h-caldesmon (maximal value, 1.7 mollmol, Fig. 1). Be- 
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Fig. 3. Initial purification of h-caldesmon phosphopeptides. Porcine 
stomach hcaldesmon was phosphorylated by MAPK, digested with 
S. aure~~ protease and purified by HPLC as described in section 2 and 
shown here. These data show the absorbance and radioactivity pro- 
files for elution of the initial digest from a Cl8 column. 
cause of the similarity of stoichiometry of MAPK phos- 
phorylation in vitro to caldesmon phosphorylated in 
intact tissues, we suspected that MAPK might also 
phosphorylate the same sites, in vitro. To test this, we 
compared phosphopeptide maps of caldesmon 
phosphorylated in intact porcine carotid arteries with 
the maps of caldesmon phosphorylated by MAPK, in 
vitro (Fig. 2). The relative mobilities of the phosphopep- 
tides were similar in the two circumstances, The main 
difference appeared to be in the relative ratio of radioac- 
tivity in the various spots. This raised the possibility 
that purified caldesmon might contain endogenous 
phosphate. As shown in Table I, an assay of 4 prepara- 
tions confirmed this suspicion. Purified caldesmon con- 
tained variable amounts of phosphate ranging from 
0.34 to 0.62 mol/mol of protein. Thus, comparison of 
relative ratios of phosphate in caldesmon, as opposed 
to mobility, was judged to be unreliable, resulting from 
Table I 
Determination of the amount of phosphate in purified h-caldesmon 
Preparation 
(IDW 
Phosphate 
(mol PO,/mol caldesmon) 
HSCD-2 0.61 + 0.05 (4) 
HSCD-3 0.51 f 0.06 (4) 
HSCD4 0.34 f 0.02 (5) 
HSCD-5 0.62 + 0.05 (4) 
h-Caldesmon was purified from hog stomachs (HSCD preparations). 
The amount of phosphate covalently bound to h-caldesmon in these 
purified preparations was then determined by the method of Buss and 
stul1 [17]. 
the likely attenuation of phosphorylation in vitro result- 
ing from the presence of significant amounts of unla- 
beled phosphate. 
3.2. Sequence of A4APK phosphorylation sites in h-cal- 
desmon 
We sequenced the sites in caldesmon phosphorylated 
by MAPK in vitro. Fig. 3 summarizes the HPLC pro- 
files of the phosphopeptides generated by digestion of 
MAPK-phosphorylated h-caldesmon with S. aureus 
protease. Four radioactive peaks were identified on the 
initial elution from a Cl8 HPLC column (Fig. 3). The 
two major peaks accounted for 83% of the total phos- 
phate incorporated into h-caldesmon. The remaining 
two peaks accounted for 10% and 7% of total incorpo- 
rated phosphate, respectively. These two minor peaks 
were subfractionated into several smaller peaks follow- 
ing anion-exchange chromatography and subsequent 
isocratic elution from a Cl8 column. However, no reli- 
able sequence could be obtained. 
The two major peaks were successfully sequenced 
and found to contain only one phosphopeptide ach. 
Peak A, containing 61% of the total phosphate incorpo- 
rated, yielded the sequence beginning with 
WLTKTPDGNKSPAPKPSDL-. In order to unam- 
biguously determine the identity of the phosphorylated 
amino acid, this peptide was further digested with en- 
doproteinase Lys-C and the resulting phosphopeptide 
purified by Cl8 HPLC. The sequence of the resulting 
phosphopeptide was S * PAPK (Table II). Peak B, con- 
taining 22% of total incorporated phosphate, yielded 
the sequence KQSVDKVTSPTKV. This peptide was 
further digested with TPCK-trypsin and the 
phosphopeptide purified by Cl8 HPLC to yield 
VTS * PTKV (Table 11). Serine was identified as the 
phosphorylated residue in both peptides A and B by 
phosphoamino acid analysis. In addition, the ratio of 
the dithiothreitol (DTT) adduct of PTH-serine to the 
amount of PTH-serine (i.e. DTT-serine/PTH-serine) 
was increased above control levels in the cycles that 
were identified as phosphoserine. 
A B 
kDa 
HeLa SMC BA HeLa SMC BA 
Fig. 4. MAPK vs. ~34~~ in smooth muscle. Proteins from cultured 
cells and frozen-ground tissues were extracted in 3% SDS gel sample 
buffer in the presence of protease inhibitors. Following SDS gel elec- 
trophoresis, the samples were transferred to nitrocellulose and evalu- 
ated for MAPK (A) or ~34~~ (B). HeLa, HeLa cells; SMC, cultured 
bovine aortic smooth muscle cells; BA, bovine aortic extract. 
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Fig. 5. Identification of MAPK cascade proteins in bovine aortic smooth muscle. Proteins were extracted from bovine aortic muscle and subjected 
to SDS-PAGE (7.5% gel) followed by Western blotting. Lanes were incubated with antibodies pecific for rus, ruJ MAPK-kinase and MAPK (A). 
MAPK-kinase was partially purified by chromatography on DEAE-Sephacel prior to immunoblotting. A proposed scheme for the mechanism of 
caldesmon phosphorylation in response to phorbol ester treatment of vascular muscle is shown in B. 
3.3. IdentiJication of other enzymes implicated in MAPK 
activation 
Although MAPK phosphorylation sites of h-cal- 
desmon in vitro are identical to those phosphorylated 
in intact vascular smooth muscle, it has not been previ- 
ously established whether all of the putative enzymes 
involved in the MAPK activation cascade are also pres- 
ent in vascular muscle. In agreement with the data of 
Childs et al. [ 111, who identified MAPK in rat aorta and 
chicken gizzard, we found MAPK in vascular tissue 
(Fig. 4A). In vascular as well as other types of smooth 
muscle that we have surveyed, antibody reactivity to- 
wards two protein bands of molecular weights 42 and 
44 kDa is routinely observed, although the relative 
amounts of p42 and p44 vary among the different tis- 
sues (data not shown). In addition, ras, raf and MAPK- 
kinase were readily identified by immunoblot of bovine 
aortic smooth muscle (Fig. 5A). While p34*“* is a po- 
Table II 
Sequences of the sites on h-caldesmon phosphorylated by MAPK 
Peptide Sequence PAA analysis Amount of total 
phosphate incorpo- 
rated into 
hcaldesmon 
A S * PAPK Serine 61% 
B VTS * PTKV Serine 22% 
C ND” Serine and threonine 10% 
D ND” Serine 7% 
Peptides corresponding to peaks A-D of Fig. 3 were sequenced to give 
the above results. Phosphoamino acid analysis of peak C showed 
approximately equal amounts of phosphoserine and phosphotbre- 
onine. 
a ND, the sequences of the phosphopeptides in these peaks could not 
be determined. 
tential candidate for caldesmon kinase based on its abil- 
ity to phosphorylate proline-directed sites in h-cal- 
desmon, we found no evidence for this enzyme in differ- 
entiated smooth muscle (Fig. 4B). Thus, the cascade 
shown in Fig. 5B could summarize the sequence of steps 
involved in caldesmon phosphorylation as it has been 
proposed for phosphorylation of ribosomal S6 kinase 
[14,30]. 
4. DISCUSSION 
The data presented in this paper provide additional 
evidence that MAPK is one of the protein kinases that 
can phosphorylate h-caldesmon in smooth muscle. In 
an earlier study, we determined that h-caldesmon iso- 
lated from phorbol ester-stimulated canine aortic mus- 
cle is phosphorylated at two sites: VTS * PTKV and 
S * PAPK [8]. This provided conclusive evidence for the 
involvement of a proline-directed protein kinase in the 
phosphorylation of caldesmon in the contractile pheno- 
type of smooth muscle. In the present study, we find 
that 83% of the phosphate incorporated into h-cal- 
desmon by MAPK is identified in the same two sites: 
VTS * PTKV and S * PAPK. The remaining 17% is in- 
corporated into sites that could not be sequenced. These 
minor site(s) may have resulted from either partial di- 
gestion of the protein by S. aurew protease or from 
phosphorylation of h-caldesmon by MAPK on alterna- 
tive sites, albeit at low stoichiometry. 
MAPK is not the only proline-directed protein kinase 
that has been reported to phosphorylate caldesmon. 
Yamashiro et al. have shown that 1-caldesmon in REF 
2A cells is phosphorylated during the M phase of the 
cell cycle, resulting in dissociation of this caldesmon 
isoform from actin [19,20]. Recently, Childs et al. have 
phosphorylated h-caldesmon in vitro [ 111. Although 
59 
Voiume 322, number 1 FEBSLETTERS May 1993 
phosphopeptide sequences were not reported, they ob- 
tained a stoichiometry of approximately 2 mol PO,/mol 
caldesmon. Through peptide mapping they concluded 
that the MAPK phosphorylation sites and those previ- 
ously reported for ~34”‘~~ must be different [21]. In the 
contractile phenotype of vascular smooth muscle there 
is no detectable p34 ulc2 by Western blotting, although 
both MAPK and ~34”~“’ can be detected in the prolifer- 
ating phenotype. Thus, MAPK is likely to serve as cal- 
desmon kinase in contracting vascular muscle. 
We have also identified other components of the 
MAPK cascade in vascular smooth muscle. Previous 
work by others has established that vascular muscle 
contains several members of the ras family [22,23]. In 
addition, we find that the protein kinases rtzf and 
MAPK-kinase (MEK) [24] are also present. Thus, cal- 
desmon phosphorylation and ribosomal S6 kinase acti- 
vation may occur in parallel since they share the same 
cascade [14]. This cascade is especially interesting since 
several growth factors and peptide hormone receptors 
are coupled to it [14,25-281. 
In conclusion, there appear to be three members of 
the caidesmon kinase family. I-Caldesmon is 
phosphorylated in intact platelets by CAMP-dependent 
protein kinase [29] and in REF 2A cells by ~34”‘“’ 
[19,20]. Our work [S] and the work of Childs et al. [ 1 I] 
provides good evidence that MAPK is an h-caldesmon 
kinase. 
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